Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Metall ZugLTS:0QLX 55 Debt-to-Equity is 0.01 as of Dec. 2025, which is 75% below its 10-year median of 0.04. GuruFocus rates LTS:0QLX with a GF Score™ of 55/100 and a GF Value™ of CHF651.04 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 702 Medical Devices & Instruments companies, Metall Zug ranks better than 99.86% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Metall Zug's Debt-to-Equity or its related term are showing as below:
LTS:0QLX'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.04 Max: 0.2
Current: 0.01
During the past 13 years, the highest Debt-to-Equity Ratio of Metall Zug was 0.20. The lowest was 0.00. And the median was 0.04.
LTS:0QLX's Debt-to-Equity is ranked better than 99.86% of 702
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs LTS:0QLX: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Metall Zug Debt-to-Equity Related Terms
Metall Zug Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Metall Zug's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0QLX vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Metall Zug's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metall Zug Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Metall Zug's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Metall Zug's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metall Zug (LTS:0QLX) has a Debt-to-Equity of 0.01 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Metall Zug and its competitors. This is 75% below median its historical median of 0.04. According to the industry distribution chart, Metall Zug ranks #1 out of 702 companies in the Medical Devices & Instruments industry, placing it in the top 0.099999999999994%.
Is Metall Zug's Debt-to-Equity too high?
Metall Zug's current Debt-to-Equity of 0.01 is 75% below median its 10-year median of 0.04. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Metall Zug's value of 0.01 is 95.7% below this industry median. Based on the distribution chart, Metall Zug ranks #1 out of 702 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Metall Zug has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Metall Zug's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Metall Zug ranks #1 out of 702 companies for Debt-to-Equity. This places Metall Zug in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.23. Metall Zug's value of 0.01 is 95.7% below this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.23, Metall Zug has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metall Zug's current Debt-to-Equity of 0.01 is 95.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Metall Zug and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metall Zug's current Debt-to-Equity is 0.01, which is 75% below median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metall Zug stock overvalued right now?
Based on GuruFocus' analysis, Metall Zug (LTS:0QLX) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF651.04, compared to a current price of CHF790.00 — trading 21.3% above its estimated fair value. The current Debt-to-Equity is 0.01, which is 75% below median its 10-year median of 0.04 and 95.7% below the Medical Devices & Instruments industry median of 0.23. Metall Zug's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Metall Zug (LTS:0QLX), the current Debt-to-Equity is 0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metall Zug (LTS:0QLX) Overvalued in 2026?
Based on GuruFocus' analysis, Metall Zug stock appears to be overvalued.
The current stock price of CHF790.00 is trading 21.3% above its estimated GF Value™ of CHF651.04.
GuruFocus considers Metall Zug to be Modestly Overvalued.
Key valuation signals for LTS:0QLX:
Debt-to-Equity: 0.01 (75% below median its 10-year median of 0.04)
GF Value™: CHF651.04 vs. price of CHF790.00 (21.3% above fair value)
Industry Position: 95.7% below the Medical Devices & Instruments median (#1 of 702)
No single metric tells the full story. See the LTS:0QLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metall Zug Ltd is engaged in the industrial sector. The company is organized, into business segments namely; Medical Devices which comprises of products and services for diagnosis and surgery, mainly in the fields of ophthalmology and microsurgery; Technologycluster & Infrastructure is engaged in Management and development of real estate; and Investments & Corporate. The majority of its revenue is generated from the Medical Devices segment. Geographically, the company operates in Switzerland, Europe (excluding Switzerland), the Americas, and Asia /Pacific/Others, and the majority of its revenue is generated from the Americas region.
55GF Score
Get the complete analysis for LTS:0QLX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QLX has been successfully added to your 
